Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies

Tanya Siddiqi,Paul Frankel,Jan H. Beumer,Brian F. Kiesel,Susan M. Christner,Chris Ruel,Joo Y. Song,Robert Chen,Kevin R. Kelly,Sikander Ailawadhi,Paul R. Kaesberg,Leslie Popplewell,Sandrine Puverel,Richard Piekarz,Stephen J. Forman,Edward M. Newman

Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies

2019

Tanya Siddiqi
Paul Frankel
Jan H. Beumer
Brian F. Kiesel
Susan M. Christner
Chris Ruel
Joo Y. Song
Robert Chen
Kevin R. Kelly
Sikander Ailawadhi
Paul R. Kaesberg
Leslie Popplewell
Sandrine Puverel
Richard Piekarz
Stephen J. Forman
Edward M. Newman

AbstractAlisertib, an Aurora kinase A inhibitor, was evaluated in a Phase 1 study in combination with the histone deacetylase inhibitor vorinostat, in patients with relapsed/refractory lymphoid mal...

Keywords:

Aurora Kinase A
Histone deacetylase inhibitor
Alisertib
Vorinostat
Aurora kinase
Cancer research
Medicine
Lymphoma
Immunology
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations